TrialJournal of clinical immunology2009

Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy.

Andrew N Cornforth et al.PubMed ↗Publisher ↗

No numbers read from the abstract.